Show simple item record

dc.contributor.advisorSharmin, Shahana
dc.contributor.authorJoya, Janifa Ferdous
dc.date.accessioned2025-01-13T04:04:01Z
dc.date.available2025-01-13T04:04:01Z
dc.date.copyright©2023
dc.date.issued2023-09
dc.identifier.otherID 18346035
dc.identifier.urihttp://hdl.handle.net/10361/25131
dc.descriptionThis thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.en_US
dc.descriptionCataloged from PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 49-54).
dc.description.abstractCancer is a dangerous disease that has plagued humanity for centuries, ranking asathe second leadingacauseaofaglobal mortality. Ina2020, nearly 20 million lives were lost to cancer, with breast cancer (BC) being the most common type. Understanding the risk factors for developing BC, such as family history, is crucial for improving survival rates. There are various treatment methods available for BC, including the use of docetaxel with monoclonal antibodies Pertuzumab & Trastuzumab, which target the overexpressed the human epidermal growth factor receptor 2 (HER2) gene in HER2-positive breast tumors. These antibodies have significantly changed the therapeutic strategy for the human epidermal growth factor receptor 2(HER2)- positive breast cancer. However, while patient results have improved, the number of people benefiting from this medication. This paper aims to explore all available BC treatments & propose a model of the synergistic effects of trastuzumab & pertuzumab, critically analyzing findings & hypotheses related to their combined activity.en_US
dc.description.statementofresponsibilityJanifa Ferdous Joya
dc.format.extent66 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectBreast canceren_US
dc.subjectCancer therapyen_US
dc.subjectPertuzumaben_US
dc.subjectTrastuzumaben_US
dc.subjectHER2en_US
dc.subjectHER family receptorsen_US
dc.subjectRisk factorsen_US
dc.subject.lcshBreast--Cancer--Genetic aspects--Chemotherapy.
dc.subject.lcshHER-2 gene.
dc.subject.lcshHER-2 protein.
dc.subject.lcshCancer--Gene therapy.
dc.titleTrastuzumab & Pertuzumab in the fight against breast cancer: mechanisms, significance, & future aspectsen_US
dc.typeThesisen_US
dc.contributor.departmentSchool of Pharmacy, Brac University
dc.description.degreeB. Pharmacy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record